Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Abnova (Taiwan)TPE:4133 -0.49%75 PB Ratio is 0.98 as of Jul. 17, 2026, which is 43% below its 10-year median of 1.72. GuruFocus rates TPE:4133 with a GF Score™ of 75/100 and a GF Value™ of NT$28.22 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,227 Biotechnology companies, Abnova (Taiwan) ranks better than 83.13% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-17), Abnova (Taiwan)'s share price is NT$20.35. Abnova (Taiwan)'s Book Value per Share for the quarter that ended in Dec. 2025 was NT$20.75. Hence, Abnova (Taiwan)'s PB Ratio of today is 0.98.
Good Sign:
Abnova (Taiwan) Corp stock PB Ratio (=1) is close to 10-year low of 0.98.
The historical rank and industry rank for Abnova (Taiwan)'s PB Ratio or its related term are showing as below:
TPE:4133'
s PB Ratio Range Over the Past 10 Years
Min: 0.97 Med: 1.72 Max: 7.65
Current: 0.98
During the past 13 years, Abnova (Taiwan)'s highest PB Ratio was 7.65. The lowest was 0.97. And the median was 1.72.
TPE:4133's PB Ratio is ranked better than 83.13% of 1227
companies
in the Biotechnology industry
Industry Median: 2.82
vs TPE:4133: 0.98
During the past 12 months, Abnova (Taiwan)'s average Book Value Per Share Growth Rate was -4.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -0.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 1.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 0.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Abnova (Taiwan) was 2.70% per year. The lowest was -1.10% per year. And the median was 0.25% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Abnova (Taiwan) PB Ratio Related Terms
Abnova (Taiwan) PB Ratio Historical Data
* Premium members only.
The historical data trend for Abnova (Taiwan)'s PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Abnova (Taiwan)'s PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abnova (Taiwan) PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abnova (Taiwan)'s PB Ratio distribution charts can be found below:
* The bar in red indicates where Abnova (Taiwan)'s PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Abnova (Taiwan)'s PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Abnova (Taiwan) (TPE:4133) has a PB Ratio of 0.98 as of Jul. 17, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Abnova (Taiwan) and its competitors. This is 43% below median its historical median of 1.72. Over the past decade, Abnova (Taiwan)'s PB Ratio has ranged from 0.97 to 7.65. According to the industry distribution chart, Abnova (Taiwan) ranks #207 out of 1227 companies in the Biotechnology industry, placing it in the top 16.9%.
Is Abnova (Taiwan)'s PB Ratio too high?
Abnova (Taiwan)'s current PB Ratio of 0.98 is 43% below median its 10-year median of 1.72. Over the past 10 years, this metric has ranged from a low of 0.97 to a high of 7.65. The Biotechnology industry median PB Ratio is 2.82. Abnova (Taiwan)'s value of 0.98 is 65.2% below this industry median. Based on the distribution chart, Abnova (Taiwan) ranks #207 out of 1227 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Abnova (Taiwan) has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abnova (Taiwan)'s PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abnova (Taiwan) ranks #207 out of 1227 companies for PB Ratio. This places Abnova (Taiwan) in the top 17% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.82. Abnova (Taiwan)'s value of 0.98 is 65.2% below this benchmark. Historically, Abnova (Taiwan)'s own PB Ratio has ranged from 0.97 to 7.65 over the past decade. While the company's 10-year median is 1.72 vs. the industry median of 2.82, Abnova (Taiwan) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abnova (Taiwan)'s current PB Ratio of 0.98 is 65.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Abnova (Taiwan) and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abnova (Taiwan)'s current PB Ratio is 0.98, which is 43% below median its own 10-year median of 1.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abnova (Taiwan) stock overvalued right now?
Based on GuruFocus' analysis, Abnova (Taiwan) (TPE:4133) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$28.22, compared to a current price of NT$20.35 — trading 27.9% below its estimated fair value. The current PB Ratio is 0.98, which is 43% below median its 10-year median of 1.72 and 65.2% below the Biotechnology industry median of 2.82. Abnova (Taiwan)'s overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Abnova (Taiwan) (TPE:4133), the current PB Ratio is 0.98 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abnova (Taiwan) (TPE:4133) Overvalued in 2026?
Based on GuruFocus' analysis, Abnova (Taiwan) stock appears to be undervalued.
The current stock price of NT$20.35 is trading 27.9% below its estimated GF Value™ of NT$28.22.
GuruFocus considers Abnova (Taiwan) to be Modestly Undervalued.
Key valuation signals for TPE:4133:
PB Ratio: 0.98 (43% below median its 10-year median of 1.72)
GF Value™: NT$28.22 vs. price of NT$20.35 (27.9% below fair value)
Industry Position: 65.2% below the Biotechnology median (#207 of 1227)
No single metric tells the full story. See the TPE:4133 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abnova (Taiwan) Corp is engaged in developing, manufacturing, and selling monoclonal antibody, polyclonal antibody, proteins, medical inspection instruments and testing reagents, which are mainly antibody reagents, antibody chips or related products provided to and used by academic, research institutions or pharmaceutical factories. Geographically, it operates in America, Europe, Taiwan and Other Countries. It generates maximum revenue from America. Its products include: SARS-CoV/CoV-2, DNA, RNA new, Proteins/peptides, MaxPab, DNAxPab, Polyclonal Ab, Monoclonal Ab and Others. The company's services are: Gene synthesis & cytogenetics, Peptide services, Protein expression, Humanized antibody, Assay development, Conjugation, FFPE tumor tissue DNA, In situ hybridization (ISH) and Others.
75GF Score
Get the complete analysis for TPE:4133
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4133 has been successfully added to your 
